Advanced Cancer Research Group, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.
Cancer Invest. 2021 Mar;39(3):205-213. doi: 10.1080/07357907.2021.1885596. Epub 2021 Feb 18.
Given the rapidly expanding global spread of the SARS-Co-V-2 virus and the expanding number of individuals with the serious and potentially fatal illness, COVID-19, there is an urgent need for safe and effective vaccines. Based on compelling evidence that patients with cancer are at increased risk for greater morbidity and mortality with COVID-19, several professional organizations have provided early guidance on the role of COVID-19 vaccines in patients with malignant disease. In this commentary we review the available data on the efficacy and safety of the approved and forthcoming vaccines in patients with cancer. Based on a review of the totality of available evidence, we recommend that most patients with cancer should receive the recommended dose and schedule of one of the COVID-19 vaccines when available. We encourage industry, regulators and professional research organizations to carefully track the efficacy and safety of COVID-19 vaccination in patients with cancer in the real world setting and routinely report unanticipated adverse events and signs of loss of efficacy. Particular attention is needed for patients on active cancer therapy to carefully evaluate efficacy and safety in relationship to the timing of vaccination relative to that of active cancer treatment and immunosuppression.
鉴于 SARS-CoV-2 病毒在全球迅速传播，以及患有严重且可能致命疾病 COVID-19 的人数不断增加，迫切需要安全有效的疫苗。基于有说服力的证据表明，癌症患者患 COVID-19 的发病率和死亡率更高，因此，一些专业组织已经就恶性疾病患者 COVID-19 疫苗的作用提供了早期指导。在这篇评论中，我们回顾了已批准和即将推出的疫苗在癌症患者中的疗效和安全性的现有数据。基于对所有现有证据的回顾，我们建议大多数癌症患者在有疫苗可用时，应按照推荐剂量和时间表接种 COVID-19 疫苗。我们鼓励行业、监管机构和专业研究组织在真实环境中仔细跟踪癌症患者 COVID-19 疫苗接种的疗效和安全性，并定期报告意外不良事件和疗效丧失的迹象。对于正在接受癌症治疗的患者，需要特别注意，要仔细评估与癌症治疗和免疫抑制相关的疫苗接种时间与疗效和安全性之间的关系。
